Press Releases Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-05-13 am EDT			5-day change	1st Jan Change
39.5 ^HKD	-4.59%		-3.42%	-7.60%

May. 07	Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	CI
Apr. 30	Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Head-to-head Superiority to High-dose Dulaglutide, Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints	May. 10	AQ
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer	May. 01	AQ
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	Apr. 17	AQ
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	Apr. 03	AQ
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer	Mar. 06	AQ
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China	Dec. 29	AQ
Innovent Releases Final Analysis Results of ORIENT-15, the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023	23-04-17	AQ
Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT in Two New Indications Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications	23-01-19	AQ
Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China	22-08-10	AQ
China NMPA Approves TYVYT (sintilimab) In Combination With Chemotherapy For Gastric Cancer	22-06-30	AQ
OPKO Health : to Develop and Commercialize RAYALDEE in Greater China with Nicoya Therapeutics	21-06-22	AQ
Innovent Biologics : Form of Proxy for use at the Annual General Meeting to be held on Thursday, June 24, 2021	21-04-30	PU
Innovent Biologics : PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE NEW SHARES, PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING	21-04-30	PU
Innovent Biologics : INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON SALES OF TYVYT (SINTILIMAB INJECTION) IN THE FIRST QUARTER OF 2021	21-04-27	PU
Innovent Biologics : GRANT OF SHARE OPTIONS AND NON-EXEMPT CONNECTED TRANSACTION - PROPOSED GRANT OF RESTRICTED SHARES TO DIRECTORS AND GRANT OF RESTRICTED SHARES	21-03-30	PU
Innovent Biologics : Announced Financial Results for Full Year Ended December 31, 2020 and Corporate Progress	21-03-30	PR
Innovent Biologics : Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody	21-02-28	PR
Innovent Biologics : and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer	21-02-02	PR
Innovent Biologics : Announces an Out-license Agreement with PT Etana Biotechnologies Indonesia to Launch BYVASDA® (Bevacizumab Biosimilar) in Indonesia	21-01-18	PR
Innovent Biologics : Announces NMPA Acceptance of a Supplemental New Drug Application for TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab injection) as First-Line Therapy in Hepatocellular Carcinoma (HCC)	21-01-12	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Press Releases

Filters